Goflikicept

Summary

Goflikicept (CHEMBL4650513) is a phase-3 clinical-stage protein (ATC L04AC26); indicated across 7 conditions including pericarditis and adult-onset still disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• ATC class: L04AC26
• Indications: 7 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650513
Name	Goflikicept
Type	Protein
Max phase	3
ATC	L04AC26

Also known as: Goflikicept, RPH 104, Rph-104, RPH-104, GOFLIKICEPT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pericarditis	3	MONDO:0005904	EFO:0007427
adult-onset Still disease	3	MONDO:0019355	EFO:0007135
immune system disorder	3	MONDO:0005046	EFO:0000540
myocardial infarction	2	MONDO:0005068	EFO:0000612
Schnitzler syndrome	2	MONDO:0018304	EFO:1001165
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
familial Mediterranean fever	2	MONDO:0018088	MONDO:0018088

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	4
PHASE2/PHASE3	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05673902	PHASE3	ACTIVE_NOT_RECRUITING	Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
NCT04380519	PHASE2/PHASE3	COMPLETED	Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
NCT04692766	PHASE2/PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis
NCT05107934	PHASE2/PHASE3	SUSPENDED	Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
NCT05432960	PHASE3	WITHDRAWN	Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still’s Disease (AOSD)
NCT05092776	PHASE2	ACTIVE_NOT_RECRUITING	Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
NCT05190991	PHASE2	RECRUITING	Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
NCT04213274	PHASE2	WITHDRAWN	Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
NCT04463251	PHASE2	COMPLETED	Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
NCT02667639	PHASE1	COMPLETED	Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
NCT07206043	PHASE1	COMPLETED	Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).